BioNotebook: Targacept gone in reverse merger with Catalyst, plus five other deals
This article was originally published in Scrip
Executive Summary
After a string of failures, Winston-Salem, North Carolina-based Targacept and its neuronal nicotinic receptor (NNR) therapeutics will be replaced by engineered human proteases for hemophilia and complement-mediated disorders in a reverse merger with privately-held Catalyst Biosciences in South San Francisco.
You may also be interested in...
Deal Watch: Bausch Health Takes Option To Allegro Dry AMD Candidate
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
Grifols Expansion Plans Include Biotech Equity, New US Manufacturing Facilities
Taking a 20% equity stake in US biotech Singulex and planning to build new manufacturing facilities in the US and Europe reflect the global expansion plans of Spain’s plasma product manufacturer Grifols, the third-largest in the world.
Finance Watch: Sironax, IDRx, OriCell Reveal First VC Mega-Rounds Of August
Private Company Edition: Sironax completed a $200m series B round while IDRx launched with $122m and OriCell raised $120m in series C funds, joining end-of-July $100m-plus fundraiser Carmot Therapeutics, which closed a $160m series D financing.